Aarey Drugs & Pharmaceuticals peers

Companies like Aarey Drugs & Pharmaceuticalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AAREYDRUGS₹108.05

Aarey Drugs & Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersNECLIFENATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹307 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
AAREYDRUGS
FY26
NECLIFE
FY26
NATCAPSUQ
FY26
MEDICAMEQ
FY26
Peer
Average
Valuation — at last close
P/E77.73×——◆ 35.21×35.21× +121%
P/B2.04×◆ 0.35×0.64×1.25×0.75× +174%
EV/EBITDA49.64×-1.25×◆ -169.48×18.31×-50.80× +198%
Market Cap₹307 Cr₹201 Cr₹142 Cr₹345 Cr₹229 Cr +34%
Growth
Revenue CAGR 3Y◆ 96.26%-81.73%—11.97%-34.88% +376%
Revenue CAGR 5Y—-64.04%——-64.04%
Net Income CAGR 3Y◆ 100.20%——-12.71%-12.71% +888%
Revenue YoY (latest Q)-56.34%-99.99%7.76%◆ 11.27%-26.99% -109%
Net Income YoY (latest Q)-25.36%◆ 75.65%-2.93%15.35%29.36% -186%
Profitability
EBITDA Margin1.52%—-0.83%◆ 9.90%4.54% -66%
Net Income Margin0.84%-3152.45%-13.17%◆ 4.95%-1053.56% +100%
Return on Common Equity2.75%-38.08%-7.51%◆ 3.95%-13.88% +120%
Return on Capital Employed2.94%-7.53%-6.12%◆ 4.92%-2.91% +201%
Return on Assets1.48%-21.95%-5.85%◆ 2.93%-8.29% +118%
Credit & Quality
Total Debt/Equity0.33×◆ 0.00×0.49×0.17×0.22× +50%
Interest Coverage0.86×-1.69×-1.71×◆ 3.54×0.05× +1743%
Scale — latest FY
Revenue / Total Income₹472 Cr₹0 Cr₹187 Cr₹198 Cr₹128 Cr +268%
Net Income₹4 Cr−₹293 Cr−₹24.7 Cr₹9.8 Cr−₹103 Cr +104%
Total Assets₹297 Cr₹622 Cr₹424 Cr₹372 Cr₹473 Cr -37%
EPS₹1.39₹-13.4₹-23.84₹7.22₹-10.01 +114%
Book Value per Share₹52.86₹29.97₹213.39₹203.17₹148.84 -64%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.